XTL Biopharmaceuticals Ltd (XTLB) stock
XTLBNasdaqPharmaceutical Preparations
$1.60−0.04 (-2.44%)
Close on Nov 13, 2026Market cap $15.14MP/E –Yield –
XTL Biopharmaceuticals r&d expenses
Research and development expenses are spending on new products and technology.
For fiscal 2025 it was $28.00K, up 75.0% from the year before. Over ten years it grew -26.1% a year on average. The highest annual figure on record is $578.00K in fiscal 2015.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $28.00K | +75.0% |
| FY2024 | Dec 31, 2024 | $16.00K | -48.4% |
| FY2023 | Dec 31, 2023 | $31.00K | +3.3% |
| FY2022 | Dec 31, 2022 | $30.00K | 0.0% |
| FY2021 | Dec 31, 2021 | $30.00K | -21.1% |
| FY2020 | Dec 31, 2020 | $38.00K | +8.6% |
| FY2019 | Dec 31, 2019 | $35.00K | -7.9% |
| FY2018 | Dec 31, 2018 | $38.00K | -11.6% |
| FY2017 | Dec 31, 2017 | $43.00K | -90.3% |
| FY2016 | Dec 31, 2016 | $443.00K | -23.4% |
| FY2015 | Dec 31, 2015 | $578.00K | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2022 | Jun 30, 2022 | $15.00K | – |
| Q2 FY2021 | Jun 30, 2021 | $6.00K | – |
| Q2 FY2020 | Jun 30, 2020 | $11.00K | – |
See a number that looks wrong?